Cepharanthine may inhibit the proliferation of prostate cells by blocking the EGFR/PI3K/AKT signaling pathway: comprehensive network analysis, molecular docking, and experimental evaluation
Abstract
Introduction Pharmacological studies have confirmed that Cepharanthine (CEP) can exert anti-inflammatory, antioxidant and anti-fibrotic effects. However, there is no systematic study on whether CEP targets and regulates the core pathological link of benign prostatic hyperplasia (BPH) - matrix hyperplasia. Methods First, the CEP structure was obtained through PubChem. Combined with BPH targets from the GeneCards/OMIM/TTD database, potential targets were obtained by intersection using Venny 2.1. Then, the PPI network was constructed using STRING, and top 20 core targets were identified using Cytoscape 3.9.1. GO/KEGG enrichment analysis was performed using the DAVID database. Based on the CB-Dock platform, CEP was molecularly docked with key targets, the protein structure was derived from AlphaFold2 and PDB, and the binding energy was calculated by the VINA algorithm. Furthermore, human prostate stromal cells WPMY-1 and benign prostatic hyperplasia cells BPH-1 were used as a model. The Celigo full-field scanning system dynamically monitored proliferation from 0 to 96 h, DNA synthesis was quantified by EdU staining, and apoptosis was detected by Annexin V-APC/PI or Annexin V-FITC/PI double staining flow cytometry. Finally, the effect of CEP on the expression of key target genes was analyzed by Western blot. Results Network analysis showed that 96 cross-targets were significantly enriched in the PI3K-AKT, MAPK and HIF-1 pathways. Molecular docking confirmed that CEP strongly…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.